Feasibility Study of CBCT for IGRT in Cancer Patients

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Varian, a Siemens Healthineers Company
Study ID
NCT06681233
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Comparison of HyperSight CBCT imaging to conventional CBCT imaging. — DEVICE
    Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.

Study Details

Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow. Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image. This study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments. The goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.

Key Dates

Start date
Feb 19, 2025
Status verified
Mar 2026
Primary completion
Aug 31, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: HyperSight Imaging Arm

Primary Outcome Measure

Comparison of Image Contrast Resolution [ Time Frame: End of radiation treatment at 9 weeks. ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
James Outpatient CenterColumbusOhio43210
Ashley Cetnar, PhD
[email protected]
614-685-5233
Nilendu Gupta, PhD
[email protected]
614-293-4204
Ashley Cetnar, PhD (PRINCIPAL_INVESTIGATOR)
Ohio State University, Brain and Spine HospitalColumbusOhio43210
Ashley Cetnar, PhD
[email protected]
614-685-5233
Nilendu Gupta, PhD
[email protected]
614-293-4204
Ashley Cetnar, PhD (PRINCIPAL_INVESTIGATOR)
Stefanie Spielman Comprehensive Breast CenterColumbusOhio43212
Ashley Cetnar, PhD
[email protected]
614-685-5233
Nilendu Gupta, PhD
[email protected]
614-293-4204
Ashley Cetnar, PhD (PRINCIPAL_INVESTIGATOR)
The Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteColumbusOhio43210
Ashley Cetnar, PhD
[email protected]
614-685-5233
Nilendu Gupta, PhD
[email protected]
614-293-4204
Ashley Cetnar, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Columbus, OH

By condition
Breast cancerLiver cancer
By specialty
OncologyBreast oncologyWomen's healthGI oncologyHepatology
By research site
James Outpatient Center· Columbus, OHOhio State University, Brain and Spine Hospital· Columbus, OHStefanie Spielman Comprehensive Breast Center· Columbus, OHThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute· Columbus, OH

Related Studies